Bovine milk-derived α-lactalbumin inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sodium sulfate-treated mice. Issue 4 (3rd April 2014)

• Record Type: Journal Article
• Authors: Yamaguchi, Makoto; Takai, Shoko; Hosono, Akira; Seki, Taiichiro
• Is Part Of: Bioscience, biotechnology, and biochemistry. Volume 78:Issue 4(2014)
• Page Start: 672
• Page End: 679
• Publication Date: 2014-04-03
• Subjects: α-lactalbumin -- cyclooxygenase -- colon carcinogenesis -- prostaglandin E2; Biotechnology -- Periodicals; Biochemistry -- Periodicals; 660.6
• DOI: 10.1080/09168451.2014.890034
• Languages: English
• ISSNs: 0916-8451

Abstract

Abstract: Cyclooxygenase-2 is expressed early in colon carcinogenesis and plays crucial role in the progress of the disease. Recently, we found that α-lactalbumin had anti-inflammatory activity by inhibiting cyclooxygenase-2. In experiment 1, we investigated the effects of α-lactalbumin on the colon carcinogenesis initiated with azoxymethane (AOM) followed by promotion with dextran sodium sulfate (DSS) in mice. Dietary treatment with α-lactalbumin decreased fecal occult blood score at 3 days after DSS intake. α-Lactalbumin also decreased the colon tumor at week 9. In experiment 2, AOM-treated mice were sacrificed at 7 days after DSS intake. The plasma and colon prostaglandin E2 (PGE2) levels in AOM/DSS-treated mice were higher than those in the DSS-treated mice without initiation by AOM. α-Lactalbumin decreased PGE2 in both plasma and colon. These results suggest that α-lactalbumin effectively inhibited colon carcinogenesis, and the inhibition may be due to the decreased PGE2 by inhibiting cyclooxygenase-2 at cancer promotion stages. Graphical abstract: : Dietary treatment with bovine milk-derived α-lactalbumin significantly decreased the number of colon tumor in azoxymethane and dextran sodium sulfate-treated mice.